A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
Latest Information Update: 05 Nov 2026
At a glance
- Drugs Emrusolmin (Primary)
- Indications Multiple system atrophy
- Focus Therapeutic Use
- Acronyms TOPAS-MSA
- Sponsors Teva Branded Pharmaceutical Products R&D
Most Recent Events
- 02 Nov 2026 An interim results were presented in a Teva Pharmaceutical Industries media release.
- 02 Nov 2026 According to Teva Pharmaceutical Industries media release, the company announced that it will work with the investigators to ensure the study protocols are followed while the study is discontinued. The company plans to share the findings with the scientific community following completion of its comprehensive analysis.
- 02 Nov 2026 Status changed from active, no longer recruiting to discontinued, the decision follows a recommendation from the independent data monitoring committee (IDMC), based on interim futility analysis, which indicated a low likelihood of meeting the primary efficacy endpoint. No safety concerns were identified.